171 related articles for article (PubMed ID: 37188824)
1. Diagnostic yield and clinical relevance of expanded germline genetic testing for nearly 7000 suspected HBOC patients.
Henkel J; Laner A; Locher M; Wohlfrom T; Neitzel B; Becker K; Neuhann T; Abicht A; Steinke-Lange V; Holinski-Feder E
Eur J Hum Genet; 2023 Aug; 31(8):925-930. PubMed ID: 37188824
[TBL] [Abstract][Full Text] [Related]
2. Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients.
Rodríguez-Balada M; Roig B; Melé M; Albacar C; Serrano S; Salvat M; Querol M; Borràs J; Martorell L; Gumà J
Clin Biochem; 2020 Feb; 76():17-23. PubMed ID: 31786208
[TBL] [Abstract][Full Text] [Related]
3. Next step in molecular genetics of hereditary breast/ovarian cancer: Multigene panel testing in clinical actionably genes and prioritization algorithms in the study of variants of uncertain significance.
Castillo-Guardiola V; Rosado-Jiménez L; Sarabia-Meseguer MD; Marín-Vera M; Macías-Cerrolaza JA; García-Hernández R; Zafra-Poves M; Sánchez-Henarejos P; Moreno-Locubiche MÁ; Cuevas-Tortosa E; Arnaldos-Carrillo M; Ayala de la Peña F; Alonso-Romero JL; Noguera-Velasco JA; Ruiz-Espejo F
Eur J Med Genet; 2022 Apr; 65(4):104468. PubMed ID: 35245693
[TBL] [Abstract][Full Text] [Related]
4. [Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery].
Arai M; Iwase T; Takazawa Y; Takeshima N
Gan To Kagaku Ryoho; 2014 Nov; 41(11):1333-9. PubMed ID: 25434434
[TBL] [Abstract][Full Text] [Related]
5. Consolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide.
Hirotsu Y; Schmidt-Edelkraut U; Nakagomi H; Sakamoto I; Hartenfeller M; Narang R; Soldatos TG; Kaduthanam S; Wang X; Hettich S; Brock S; Jackson DB; Omata M
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486089
[No Abstract] [Full Text] [Related]
6. Criteria of the German Consortium for Hereditary Breast and Ovarian Cancer for the Classification of Germline Sequence Variants in Risk Genes for Hereditary Breast and Ovarian Cancer.
Wappenschmidt B; Hauke J; Faust U; Niederacher D; Wiesmüller L; Schmidt G; Groß E; Gehrig A; Sutter C; Ramser J; Rump A; Arnold N; Meindl A
Geburtshilfe Frauenheilkd; 2020 Apr; 80(4):410-429. PubMed ID: 32322110
[TBL] [Abstract][Full Text] [Related]
7. Multigene panel testing for hereditary breast and ovarian cancer in the province of Ontario.
Lerner-Ellis J; Mighton C; Lazaro C; Watkins N; Di Gioacchino V; Wong A; Chang MC; Charames GS
J Cancer Res Clin Oncol; 2021 Mar; 147(3):871-879. PubMed ID: 32885271
[TBL] [Abstract][Full Text] [Related]
8. Changes in classification of genetic variants in BRCA1 and BRCA2.
Kast K; Wimberger P; Arnold N
Arch Gynecol Obstet; 2018 Feb; 297(2):279-280. PubMed ID: 29302806
[TBL] [Abstract][Full Text] [Related]
9. Germline Pathogenic Variant Prevalence Among Latin American and US Hispanic Individuals Undergoing Testing for Hereditary Breast and Ovarian Cancer: A Cross-Sectional Study.
Ossa Gomez CA; Achatz MI; Hurtado M; Sanabria-Salas MC; Sullcahuaman Y; Chávarri-Guerra Y; Dutil J; Nielsen SM; Esplin ED; Michalski ST; Bristow SL; Hatchell KE; Nussbaum RL; Pineda-Alvarez DE; Ashton-Prolla P
JCO Glob Oncol; 2022 Jul; 8():e2200104. PubMed ID: 35867948
[TBL] [Abstract][Full Text] [Related]
10. Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast/ovarian cancer using the ACMG/AMP 2015 guidelines.
So MK; Jeong TD; Lim W; Moon BI; Paik NS; Kim SC; Huh J
Breast Cancer; 2019 Jul; 26(4):510-519. PubMed ID: 30725392
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic cancer as a sentinel for hereditary cancer predisposition.
Young EL; Thompson BA; Neklason DW; Firpo MA; Werner T; Bell R; Berger J; Fraser A; Gammon A; Koptiuch C; Kohlmann WK; Neumayer L; Goldgar DE; Mulvihill SJ; Cannon-Albright LA; Tavtigian SV
BMC Cancer; 2018 Jun; 18(1):697. PubMed ID: 29945567
[TBL] [Abstract][Full Text] [Related]
12. Interdisciplinary risk counseling for hereditary breast and ovarian cancer: real-world data from a specialized center.
Zang B; Helms M; Besch L; Kalmbach N; Stegen S; Blohmer JU; Speiser D
Arch Gynecol Obstet; 2023 May; 307(5):1585-1592. PubMed ID: 36307613
[TBL] [Abstract][Full Text] [Related]
13. Clinical Validity of Next-Generation Sequencing Multi-Gene Panel Testing for Detecting Pathogenic Variants in Patients With Hereditary Breast-Ovarian Cancer Syndrome.
Yoo J; Lee GD; Kim JH; Lee SN; Chae H; Han E; Kim Y; Kim M
Ann Lab Med; 2020 Mar; 40(2):148-154. PubMed ID: 31650731
[TBL] [Abstract][Full Text] [Related]
14. Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations.
Tsaousis GN; Papadopoulou E; Apessos A; Agiannitopoulos K; Pepe G; Kampouri S; Diamantopoulos N; Floros T; Iosifidou R; Katopodi O; Koumarianou A; Markopoulos C; Papazisis K; Venizelos V; Xanthakis I; Xepapadakis G; Banu E; Eniu DT; Negru S; Stanculeanu DL; Ungureanu A; Ozmen V; Tansan S; Tekinel M; Yalcin S; Nasioulas G
BMC Cancer; 2019 Jun; 19(1):535. PubMed ID: 31159747
[TBL] [Abstract][Full Text] [Related]
15. HBOC multi-gene panel testing: comparison of two sequencing centers.
Schroeder C; Faust U; Sturm M; Hackmann K; Grundmann K; Harmuth F; Bosse K; Kehrer M; Benkert T; Klink B; Mackenroth L; Betcheva-Krajcir E; Wimberger P; Kast K; Heilig M; Nguyen HP; Riess O; Schröck E; Bauer P; Rump A
Breast Cancer Res Treat; 2015 Jul; 152(1):129-136. PubMed ID: 26022348
[TBL] [Abstract][Full Text] [Related]
16. BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
Alemar B; Gregório C; Herzog J; Matzenbacher Bittar C; Brinckmann Oliveira Netto C; Artigalas O; Schwartz IVD; Coffa J; Alves Camey S; Weitzel J; Ashton-Prolla P
PLoS One; 2017; 12(11):e0187630. PubMed ID: 29161300
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive custom panel evaluation for routine hereditary cancer testing: improving the yield of germline mutation detection.
Velázquez C; Lastra E; Avila Cobos F; Abella L; de la Cruz V; Hernando BA; Hernández L; Martínez N; Infante M; Durán M
J Transl Med; 2020 Jun; 18(1):232. PubMed ID: 32522261
[TBL] [Abstract][Full Text] [Related]
18. Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center.
Arun BK; Peterson SK; Sweeney LE; Bluebond RD; Tidwell RSS; Makhnoon S; Kushwaha AC
Cancer; 2022 Jan; 128(1):94-102. PubMed ID: 34424535
[TBL] [Abstract][Full Text] [Related]
19. Next Generation Sequencing-Based Germline Panel Testing for Breast and Ovarian Cancers in Pakistan.
Tariq H; Gul A; Khadim T; Ud-Din H; Tipu HN; Asif M; Ahmed R
Asian Pac J Cancer Prev; 2021 Mar; 22(3):719-724. PubMed ID: 33773534
[TBL] [Abstract][Full Text] [Related]
20. Germline variants in DNA repair genes associated with hereditary breast and ovarian cancer syndrome: analysis of a 21 gene panel in the Brazilian population.
da Costa E Silva Carvalho S; Cury NM; Brotto DB; de Araujo LF; Rosa RCA; Texeira LA; Plaça JR; Marques AA; Peronni KC; Ruy PC; Molfetta GA; Moriguti JC; Carraro DM; Palmero EI; Ashton-Prolla P; de Faria Ferraz VE; Silva WA
BMC Med Genomics; 2020 Feb; 13(1):21. PubMed ID: 32039725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
